Common Contracts
48 similar Capital on Demand Sales Agreement contracts by Actinium Pharmaceuticals, Inc., Aileron Therapeutics Inc, Galmed Pharmaceuticals Ltd., others
Galmed Pharmaceuticals Ltd. Ordinary Shares (NIS 1.80 par value per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • November 14th, 2024 • Galmed Pharmaceuticals Ltd. • Pharmaceutical preparations • New York
Galmed Pharmaceuticals Ltd., a company organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Galmed Pharmaceuticals Ltd. Ordinary Shares (NIS 1.80 par value per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • November 14th, 2024 • Galmed Pharmaceuticals Ltd. • Pharmaceutical preparations • New York
Galmed Pharmaceuticals Ltd., a company organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Lexaria Bioscience Corp Common Stock ($0.001 par value per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • August 22nd, 2024 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
Lexaria Bioscience Corp, a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • August 16th, 2024 • NeuroSense Therapeutics Ltd. • Pharmaceutical preparations • New York
NeuroSense Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Beyond, Inc. Common Stock ($0.0001 par value per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • June 10th, 2024 • Beyond, Inc. • Retail-catalog & mail-order houses • New York
BEYOND, INC. a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JONESTRADING INSTITUTIONAL SERVICES LLC (the “Agent”), as follows:
Common Stock (par value $0.01 per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • June 3rd, 2024 • Elicio Therapeutics, Inc. • Pharmaceutical preparations • New York
Elicio Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
VIRIOS THERAPEUTICS, INC. Common Stock ($0.0001 par value per share)Capital on Demand Sales Agreement • July 14th, 2023 • Virios Therapeutics, Inc. • Pharmaceutical preparations • New York
Virios Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Capital On DemandTM Sales AgreementCapital on Demand Sales Agreement • May 1st, 2023 • Cassava Sciences Inc • Pharmaceutical preparations • New York
Cassava Sciences, Inc. a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • April 14th, 2023 • BioRestorative Therapies, Inc. • Services-misc health & allied services, nec • New York
BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • December 22nd, 2022 • NEUROONE MEDICAL TECHNOLOGIES Corp • Surgical & medical instruments & apparatus • New York
NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
EVAXION BIOTECH A/S American Depositary Shares Representing Ordinary Shares DKK 1 nominal value each Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • October 4th, 2022 • Evaxion Biotech a/S • Biological products, (no disgnostic substances) • New York
HCW Biologics Inc. Common Stock ($0.0001 par value per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • August 19th, 2022 • HCW Biologics Inc. • Pharmaceutical preparations • New York
HCW Biologics Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • August 16th, 2022 • Unicycive Therapeutics, Inc. • Pharmaceutical preparations • New York
Unicycive Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Amended and Restated Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • June 29th, 2022 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Monopar Therapeutics Inc. Common Stock ($0.001 par value per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • April 20th, 2022 • Monopar Therapeutics • Pharmaceutical preparations • New York
Monopar Therapeutics Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Capital On Demand™ Sales AgreementCapital on Demand Sales Agreement • March 12th, 2021 • Adicet Bio, Inc. • Pharmaceutical preparations • New York
Adicet Bio, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services, LLC (the “Agent”) as follows:
OCUPHIRE PHARMA, INC.Capital on Demand Sales Agreement • March 11th, 2021 • Ocuphire Pharma, Inc. • Pharmaceutical preparations • New York
Ocuphire Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • February 12th, 2021 • CNS Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Aileron Therapeutics, Inc. Common Stock ($0.001 par value per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • January 29th, 2021 • Aileron Therapeutics Inc • Pharmaceutical preparations • New York
Aileron Therapeutics, Inc., a Delaware corporation (the “Company”) confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (“JonesTrading”) and William Blair & Company, L.L.C. (“William Blair”; each of JonesTrading and William Blair individually an “Agent” and collectively, the “Agents”) as follows:
Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • August 7th, 2020 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
ARCA biopharma, Inc.Capital on Demand Sales Agreement • July 22nd, 2020 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • New York
ARCA biopharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Overstock.com, Inc. Common Stock ($0.0001 par value per share) Amended and Restated Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • June 29th, 2020 • OVERSTOCK.COM, Inc • Retail-catalog & mail-order houses • New York
Overstock.com, Inc. a Delaware corporation (the “Company”) and JonesTrading Institutional Services LLC (“JonesTrading”) are parties to that certain Capital on Demand™ Sales Agreement dated August 9, 2018, as amended on March 15, 2019, November 12, 2019 and April 9, 2020 (together, the “Original Agreement”). Together with D.A. Davidson & Co. (“D.A. Davidson”; each of JonesTrading and D.A. Davidson individually an “Agent” and together, the “Agents”), the Company and the Agents desire to amend and restate the Original Agreement as set forth in this agreement (this “Agreement”), and hereby agree as follows:
Surface Oncology, Inc. Common Stock ($0.0001 par value per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • May 22nd, 2020 • Surface Oncology, Inc. • Biological products, (no disgnostic substances) • New York
Surface Oncology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
CURIS, INC. Common Stock ($0.01 par value per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • March 6th, 2020 • Curis Inc • Biological products, (no disgnostic substances) • New York
Curis, Inc. (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Monopar Therapeutics Inc. Common Stock ($0.001 par value per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • January 13th, 2020 • Monopar Therapeutics • Pharmaceutical preparations • New York
Monopar Therapeutics Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
INFINITY PHARMACEUTICALS, INC. Shares of Common Stock (par value $0.001 per share) Amended and Restated Capital on DemandTM Sales AgreementCapital on Demand Sales Agreement • July 30th, 2019 • Infinity Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Aileron Therapeutics, Inc. Common Stock ($0.001 par value per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • July 1st, 2019 • Aileron Therapeutics Inc • Pharmaceutical preparations • New York
Aileron Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
INFINITY PHARMACEUTICALS, INC. Shares of Common Stock (par value $0.001 per share) Capital on DemandTM Sales AgreementCapital on Demand Sales Agreement • June 28th, 2019 • Infinity Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Infinity Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading International Services LLC (the “Agent”), as follows:
Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • May 16th, 2019 • BioPharmX Corp • Pharmaceutical preparations • New York
BioPharmX Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Surface Oncology, Inc. Common Stock ($0.0001 par value per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • May 1st, 2019 • Surface Oncology, Inc. • Biological products, (no disgnostic substances) • New York
Surface Oncology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JONESTRADING INSTITUTIONAL SERVICES LLC (the “Agent”), as follows:
CELSION CORPORATION Shares of Common Stock (par value $0.01 per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • December 5th, 2018 • Celsion CORP • Pharmaceutical preparations • New York
Celsion Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
Class A Common Stock ($0.01 par value per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • August 10th, 2018 • Standard Diversified Inc. • Tobacco products • New York
STANDARD DIVERSIFIED INC. a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JONESTRADING INSTITUTIONAL SERVICES LLC (the “Agent”), as follows:
Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • August 9th, 2018 • OVERSTOCK.COM, Inc • Retail-catalog & mail-order houses • New York
OVERSTOCK.COM, INC. a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JONESTRADING INSTITUTIONAL SERVICES LLC (the “Agent”), as follows:
Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • February 9th, 2018 • Pain Therapeutics Inc • Pharmaceutical preparations • New York
PAIN THERAPEUTICS, INC. a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JONESTRADING INSTITUTIONAL SERVICES LLC (the “Agent”), as follows:
Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • July 10th, 2017 • Preferred Apartment Communities Inc • Real estate investment trusts • New York
Preferred Apartment Communities, Inc., a Maryland corporation (the "Company") confirms its agreement (this "Agreement") with JMP Securities LLC, (the "Agent"), as follows:
